Compare EFC & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFC | HROW |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2010 | N/A |
| Metric | EFC | HROW |
|---|---|---|
| Price | $13.62 | $40.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $14.46 | ★ $68.86 |
| AVG Volume (30 Days) | ★ 1.5M | 683.4K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | ★ 11.46% | N/A |
| EPS Growth | ★ 1.22 | N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $329,815,000.00 | $250,042,000.00 |
| Revenue This Year | N/A | $43.92 |
| Revenue Next Year | $8.81 | $41.22 |
| P/E Ratio | $10.22 | ★ N/A |
| Revenue Growth | 13.84 | ★ 47.83 |
| 52 Week Low | $11.12 | $20.85 |
| 52 Week High | $14.40 | $50.72 |
| Indicator | EFC | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 49.44 | 54.51 |
| Support Level | $13.30 | $39.64 |
| Resistance Level | $14.04 | $42.44 |
| Average True Range (ATR) | 0.20 | 2.24 |
| MACD | -0.02 | 0.35 |
| Stochastic Oscillator | 42.57 | 64.90 |
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.